BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $481,972 | -99.9% | 9,456 | -99.9% | 0.00% | -99.9% |
| Q3 2022 | $462,625,000 | -37.0% | 8,589,401 | -24.8% | 3.83% | -30.1% |
| Q2 2022 | $733,937,000 | -23.1% | 11,426,694 | -7.2% | 5.48% | -6.3% |
| Q1 2022 | $954,794,000 | -9.0% | 12,313,561 | +0.7% | 5.85% | -0.7% |
| Q4 2021 | $1,049,159,000 | +17.3% | 12,222,261 | +9.9% | 5.89% | +14.7% |
| Q3 2021 | $894,758,000 | +6.0% | 11,124,677 | +6.1% | 5.14% | +8.5% |
| Q2 2021 | $844,134,000 | -10.7% | 10,486,135 | -6.4% | 4.73% | -8.6% |
| Q1 2021 | $945,295,000 | +6.0% | 11,208,149 | +0.9% | 5.18% | -2.7% |
| Q4 2020 | $891,477,000 | +1.2% | 11,110,132 | +1.4% | 5.32% | -13.0% |
| Q3 2020 | $880,915,000 | +14.4% | 10,953,932 | +22.5% | 6.12% | +8.5% |
| Q2 2020 | $769,943,000 | +5.9% | 8,942,428 | -0.1% | 5.64% | -2.4% |
| Q1 2020 | $726,890,000 | +19.7% | 8,952,949 | +23.3% | 5.77% | +10.9% |
| Q4 2019 | $607,386,000 | +8.7% | 7,263,649 | +13.7% | 5.21% | -4.3% |
| Q3 2019 | $558,658,000 | -13.5% | 6,386,849 | -19.0% | 5.44% | -1.2% |
| Q2 2019 | $645,908,000 | +1.2% | 7,886,549 | +0.5% | 5.51% | -4.0% |
| Q1 2019 | $638,361,000 | +24.8% | 7,850,949 | +1.0% | 5.74% | +21.0% |
| Q4 2018 | $511,641,000 | +39.2% | 7,773,341 | +63.0% | 4.74% | +53.2% |
| Q3 2018 | $367,569,000 | -43.8% | 4,768,052 | -46.1% | 3.10% | -42.3% |
| Q2 2018 | $653,632,000 | +5.3% | 8,852,005 | -7.3% | 5.36% | +6.8% |
| Q1 2018 | $620,774,000 | -3.7% | 9,544,502 | -4.3% | 5.02% | +0.3% |
| Q4 2017 | $644,920,000 | +1.8% | 9,977,102 | -1.2% | 5.01% | -3.3% |
| Q3 2017 | $633,474,000 | +2.8% | 10,095,202 | -0.8% | 5.18% | +7.6% |
| Q2 2017 | $616,243,000 | +19.4% | 10,179,102 | +2.3% | 4.81% | +3.3% |
| Q1 2017 | $516,098,000 | +21.0% | 9,951,759 | +3.5% | 4.66% | +2.7% |
| Q4 2016 | $426,420,000 | -3.6% | 9,617,059 | +3.5% | 4.53% | -9.5% |
| Q3 2016 | $442,163,000 | +7.1% | 9,289,142 | +1.7% | 5.01% | +10.4% |
| Q2 2016 | $412,969,000 | -1.3% | 9,132,431 | -10.3% | 4.54% | -13.3% |
| Q1 2016 | $418,260,000 | +3.5% | 10,181,599 | -3.9% | 5.24% | +3.2% |
| Q4 2015 | $404,113,000 | +43.1% | 10,592,749 | +23.3% | 5.07% | +33.7% |
| Q3 2015 | $282,318,000 | -47.1% | 8,594,150 | +12.5% | 3.80% | -49.6% |
| Q2 2015 | $534,017,000 | +16.5% | 7,636,450 | +14.1% | 7.53% | +4.3% |
| Q1 2015 | $458,275,000 | -2.8% | 6,690,150 | +4.0% | 7.22% | -3.1% |
| Q4 2014 | $471,383,000 | +57.4% | 6,431,751 | +54.2% | 7.45% | +56.0% |
| Q3 2014 | $299,417,000 | -43.4% | 4,171,900 | -42.9% | 4.78% | +6.9% |
| Q2 2014 | $528,628,000 | +106.6% | 7,311,600 | +110.2% | 4.47% | -1.7% |
| Q1 2014 | $255,882,000 | +2242.0% | 3,477,600 | +2113.6% | 4.54% | +1955.7% |
| Q4 2013 | $10,926,000 | – | 157,100 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |